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1,4-dioxane is an environmental toxin found in drinking water that is highly associated 
with liver cancer. The interactions between environmental toxins and the human body can result 
in the development of tumorigenesis, it can also result in changes to metabolism and thus 
metabolites that circulate within the body. Some of these metabolites can be procarcinogenic, or 
can reflect changes to host processes that control metabolism. Stool contains copious information 
on metabolism that can provide an overview of the well-being of our body, and metabolites in the 
stool can provide information regarding the pathogenesis of disease and the toxicokinetics of 
toxicants.  Particularly, bile acids, products of cholesterol that are metabolized initially in the liver, 
and then further processed in the intestine by microbial enzymes can be measured in the stool.  In 
this study, we exposed mice to 5000 mg/L 1,4-dioxane in their drinking water and collected their 
stool at one week. Targeted metabolomics was performed to analyze bile acid concentrations, 
while untargeted metabolomics was performed as a discovery approach to identify novel 
metabolites of 1,4-dioxane exposure. Both approaches were performed using UHPLC coupled 
with Q-TOF mass spectrometry. Targeted bile acids metabolomics was analyzed with multiple 
comparison t-test with Benjamini, Krieger and Yekutieli correction. Untargeted multivariate 
analysis was analyzed with unsupervised principal component analysis and further analyzed with 
supervised partial least-squares discriminant analysis (PLS-DA) and orthogonal projection to 
latent structure analysis (OPLS-DA). The identified features and metabolites were further analyzed 
with multiple comparison t-test with Benjamini, Krieger and Yekutieli correction. In our study, a 
trend of bile acid biosynthesis dysregulation was observed, suggesting upregulation of lithocholic 
acid (LCA) and hyodeoxycholic acid (HDCA) in the exposed mice. Vitamin E, threonine, and 
citrulline were also found to be down regulated, suggesting disturbances in metabolism associated 
with antioxidant activity, urea cycle and coenzyme A synthesis. Overall, exposure to 1,4-dioxane 
dysregulated bile acid metabolism and potentially induced oxidative damage that is greatly 
associated with liver cancer. This increased understanding of the environment–host interactions 
brings about significant opportunities to create new therapeutic and surveillance approaches to 
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     1,4-dioxane is a common solvent stabilizer used in foods, cosmetics, and detergents. Its 
high solubility and stability hinder its bio-degradability in water. It is found in groundwater and 
surface water across the United States, which has made it a potential source of environmental 
contamination1. 1,4-dioxane is a hazardous substance in the Agency for Toxic Substances and 
Disease Registry (ATSDR) 2017 substance priority list, and poses a potential threat to human 
health based on its demonstrated toxicity, carcinogenesis and potential for human exposure2. The 
International Agency for Research on Cancer has classified 1,4-dioxane as a group 2B carcinogen 
with the primary target in animal studies being the liver. Despite this concern3, there are no federal 
or state maximal contaminant levels (MCLs) and a wide range of drinking water guidelines, from 
0.3-70 ppb across the US4. This is partly because the cancer mechanisms are unknown, which 
results in different interpretations of the risk at low dose. 
1,4-dioxane is rapidly metabolized to 1,4-dioxane-2-one and 2 b- hydroxyethoxyacetic 
acid (HEAA), but the pathway of metabolism is still not clear1,5,6. Cytochrome 450s are thought to 
detoxify the intermediates produced7. The half-life for 1,4-dioxane elimination has been reported 
to be 59 min, and 99.3% of the elimination was by metabolism to HEAA6. A number of studies in 
humans have shown that en route to HEAA, 1,4-dioxane  is first metabolized to diethylene glycol 
(DEG) followed by conversion of DEG to 2-hydroxyethoxyacetaldehyde, which is rapidly 
metabolized to HEAA and then to diglycolic acid (DGA)6,8,9. Both DEG and DGA have been 
shown to cause mitochondrial dysfunction and nephrotoxicity, leading to the possibility that they 
are also involved in 1,4-dioxane induced liver toxicity10,11. 1,4-dioxane and its metabolic 
breakdown products could be metabolized within the human intestine to more reactive metabolites 
that could be subject to systemic absorption and transport to the liver. Microbiome metabolism 
leading to toxic metabolites has been shown for a number of other environmental chemicals12,13. 
Metabolism of 1,4-dioxane via intestinal microbiome is rapid and some percentage of formed 
metabolites are excreted in feces fast. It could be utilized to evaluate systemic exposure to 
potentially novel toxic metabolites, including 1,4-dioxane. Metabolomics is a promising approach 
for the identification of changes in biochemical signatures associated with the pathogenesis that 
could be used for diagnosis. 
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In our previous pilot study performed in the Vasiliou and Johnson Labs at Yale School of 
Public Health, that investigated the effects of 1,4-dioxane on the liver in a mouse model, we 
discovered at one-week exposure to 1,4-dioxane, the number of hepatocytes staining positively for 
γ-H2AX, a marker of DNA double strand breaks, was significantly increased at the dose of 5,000 
mg/L (P<0.05). Also, at one-week exposure of 1,4-dioxane, the number of non-hepatocytes, 
macrophages in particular, staining positive for γ-H2AX was significantly elevated at the dose of 
500 mg/L (P<0.05).  After four weeks of exposure to 5,000 mg/L 1,4-dioxane, the number of γ-
H2AX-positive hepatocytes remained significantly elevated (P<0.05) relative to control. 
Moreover, a marker of precholangiocyte cellularity, CK7, was significantly increased in the livers 
of mice treated with 5,000 mg/L 1,4-dioxane for four weeks (P<0.05). Further, our previous study 
also discovered salvage pathways responsible for DNA repair mechanisms were altered, including 
adenine and adenosine salvage (p=0.048). Pathways that are responsible for oxidative stress 
response, detoxification, DNA damage, and lipid metabolism were dysregulated, in particular bile 
acid biosynthesis and FXR/RXR activation that are associated with non-alcoholic steatohepatitis 
hepatocellular carcinoma in mice. Glutathione-mediated detoxification pathway that related to 
oxidative damage to proteins and DNA were also dysregulated. Overall, our preliminary data 
suggested 1,4-dioxane could serve as a promoter of liver carcinogenesis by impairing cellular 
defenses against oxidative stress.  
Bile acids are produced in the liver and as such are often used to evaluate liver function 
clinically. They are circulated in blood and secreted into the stool and urine. Like tissue sampling 
and blood draw, the stool metabolome can also represent the bio-function of human body, 
including liver14. Stool metabolomics is a non-invasive approach that could be utilized to measure 
environmental exposure and provide holistic insight of the toxicants and their metabolic pathways. 
In this study, we performed metabolomics assays using UHPLC coupled with Q-TOF mass 
spectrometry to characterize the metabolic changes in the stool that result from  1,4-dioxane 
exposure. We focused our efforts on the targeted analysis of bile acids and performed a discovery 
based untargeted approach to examine novel metabolic pathway disruption. Our aim was to 
discover potential biomarkers that could be used in future biological assessment for 1,4-dioxane 







All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
unless otherwise specified. 
 
Animals	
In-house bred BDF-1 mice were group-housed, maintained on a 12-h light-dark cycle, with 
free access to regular chow and water ad libitum. At six weeks of age, all mice will be administered 
either no 1,4-dioxane or 5000mg/L 1,4-dioxane in their drinking water for 1 week. Stools were 
collected, flash frozen in liquid nitrogen and stored at −80 °C for latter metabolomics. All animal 
procedures were approved by and conducted in compliance with the Institutional Animal Care and 




Frozen stool (25 mg) were homogenized with 200 µL H2O for three cycles (each cycle:  
5500rpm for 20 secs). Samples were further mixed in buffer MeOH/ ACN (1:1) and Vortexed for 
30 secs, followed by sonication for 10 min in 4 ℃ water bath. Next, samples were Incubated for 2 
hours at -20 ℃ and then centrifuged for 15 min at 13000 rpm at 4 ℃. Supernatant fluid (450 µL) 
was taken supernatant into a 1.5 mL microcentrifuge tube and then evaporated to dryness.  
Reconstitution buffer ACN: H2O (1:1, 100uL) were added into a microcentrifuge tube for HILIC-
MS analysis. After vortex for 30 secs and sonication for 10 min (in 4 ℃ water bath), samples were 
centrifuged for 15 min at 13000 rpm and 4 ℃.  The supernatant fluid was taken and diluted 5 times 






Both HILIC-MS and RPLC-MS approaches were used for comprehensive metabolome 
profiling. An UPLC system (ACQUITY, Waters Corporation, Millford, USA) coupled to a 
quadruple time-of flight (QTOF) mass spectrometer (Xevo GS-XS QTOF, Waters Corporation, 
Millford, USA) was used for metabolomics data acquisition. Waters ACQUITY UPLC BEH 
Amide column (particle size, 1.7 µm; 100 mm (length) × 2.1 mm (i.d.)) and Waters ACQUITY 
UPLC BEH C18 column (particle size, 1.7 µm; 50 mm (length) × 2.1 mm (i.d.)) were used for the 
LC separation and the column temperature was kept at 25oC. The flow rate was 0.5 mL/min and 
the sample injection volume was 1 µL. For Amide column, the mobile phase A was 25 mM 
NH4OH and 25 mM NH4OAc in water, while the mobile phase B was ACN for both positive 
mode (ESI+) and negative mode (ESI-), respectively. The linear gradient was set as follows: 0 ~ 
0.5 min: 95% B; 0.5 ~ 7 min: 95% B to 65% B; 7 ~ 8 min: 65% B to 40% B; 8 ~ 9 min: 40% B; 9 
~ 9.1 min: 40% B to 95% B; 9.1 ~ 12 min: 95% B. For C18 column, the mobile phases A was 
0.1% FA in water, while the mobile phases B was 0.1% FA in ACN, respectively. The linear 
gradient was set as follows: 0 ~ 1 min: 1% B; 1 ~ 8 min: 1% B to 100% B; 8 ~ 10 min: 100% B; 
10 ~ 10.1 min: 100% B to 1% B; 10.1 ~ 12 min: 1% B. QC samples were analyzed every eight 
injections of biological samples to monitor the stability of the data acquisition and used for data 
normalization. 
TOF-MS scan data (300 ms/scan; mass scan range 50-1000 Da) was firstly acquired for each 
biological sample. Then MSe (low energy scan:200 ms/scan, collision energy 6 eV; high energy 
scan: 100 ms/scan, collision energy 40 eV, mass scan range 25-1000 Da) data were acquired for 
metabolite identification.  ESI source parameters on Xevo GS-XS QTOF were set as followings: 
capillary voltage 1.8 kV, sampling cone 40 V, source temperature 50 °C, desolvation temperature 
550 °C, cone gas flow 40 L/Hr, desolvation gas flow 900 L/Hr.  
 
Targeted	analysis	of	bile	acids	
ToF-multiple reaction monitoring (MRM) mode was used to quantify bile acids with target 
enhancement, in which a precursor ion is selected by the quadrupole and fragmented in the 
collision cell. The ToF pusher is synchronized with the mass-to-charge ratio (m/z) of the precursor 
or a product ion, maximizing the duty cycle for a target m/z range and effecting an increase in 
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response and selectivity. The MRM transitions (parent ion m/z Da / product ion m/z Da) of bile 
acids are listed as follows: CA (407.2802 Da /407.2802 Da), CDCA (391.2853 Da /391.2853 Da), 
DCA (391.2853 Da /391.2853 Da), HDCA (391.2853 Da /391.2853 Da), LCA (375.2904 Da 
/375.2904 Da), UDCA (391.2853 Da /391.2853 Da), TCA (514.2843 Da /79.9568 Da), TCDCA 
(498.2894 Da /79.9568 Da), TDCA (498.2894 Da /79.9568 Da), GDCA (448 Da /74.0244 Da), 
GHDCA (448 Da /74.0244 Da). Standard curves were made for each bile acid with serial dilution 
of standards: 1.6 ng/mL, 5 ng/mL, 16 ng/mL, 50 ng/mL, 160 ng/mL, 500 ng/mL, 1600 ng/mL. 
 
LC-MS	data	processing	
For untargeted metabolomics data, the raw MS data (.raw) were converted to mzML files 
using ProteoWizard MSConvert (version 3.0.6150) and processed using XCMS under R 
programming language for feature detection, retention time correction and alignment. Part of 
XCMS processing parameters were optimized and set as followings: mass accuracy in peak 
detection = 20 ppm; peak width c = (2, 20); snthresh = 6; bw = 10; minfrac = 0.5. R package 
CAMERA was used for peak annotation after XCMS data processing15. The resulting raw data 
was then preprocessed for data normalization using SVR algorithm by R language. The 
metabolites were identified by matching parent m/z value, MS/MS spectrum and retention time 
with in house library.  
For targeted quantitative data of bile acids, data analysis and quantification were carried out using 
TargetLynx® software (Waters Corporation) by integrating peak areas of extracted ion 
chromatograms. The concentration of each metabolite was calculated by comparison to a standard 
curve of an authentic standard, as previously described. 
 
Statistical	analysis	
MetaboAnalyst (https://www.metaboanalyst.ca/) was used to generate the hierarchy 
clustering heat map of a differential abundance of metabolites between exposure and control; 
P < 0.05 by two-tailed Student's unpaired t-test was used as the significance cut-off criteria16. 
Metabolic features with RSD<30% are subjected to multivariate analysis (PLS-DA and OPLS-
DA). Group differences in individual metabolite quantitation were analyzed using the GraphPad 
Prism version 8.0 for Windows, GraphPad Software, La Jolla California USA  by two-tailed 
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In order to examine the changes in stool biomarkers that correlate with bile circulation, the 
abundance of related metabolites was examined. A battery of metabolites involved in bile acid 
metabolism were found to be affected in the exposed group, but not significantly in our study 
(Figure 1). Metabolites LCA and HDCA showed a trend to be upregulated (p = 0.12, 0.12, 
respectively). Moreover, the ratio of TCA/CA (p=0.31) may suggest a trend of decrease in 1,4-
dioxane exposed group. These observations indicated that changes in stool metabolic signatures 
may reflect extensive reprogramming of the bile acid metabolic pathway when exposed to 1,4-
dioxane. Bile acids metabolites were summarized in Table 1 with their corresponding p-value, q-
value, and differences by group. 
 
Exposure	to	1,4-dioxane	Develop	Distinct	Metabolic	Traits	
Eight stool samples were analyzed at week one in order to investigate the metabolite 
differences in exposed group and control group. A total of 505 metabolic features were detected 
in the stool samples that matched the %RSD (<30%) criteria from the respective pooled QC 
samples.  
To determine the metabolomic difference between 1,4-dioxane exposed group and control 
group, we performed unsupervised hierarchical clustering on normalized peak values. It produced 
two major clades broadly classified with exposed group and control group (Figure 2).  The heat 
map indicated samples in the control group were mostly divided from samples in the exposed 
group, while internal variation may exist.   
Principal component analysis (PCA) was then used as an unsupervised statistical method 
to study differences in the metabolome between the 1,4-dioxane exposed group and control. A 
score plot provided a direct image of observational clusters. As shown in figures 3, the clustering 
showed modest separation between the 1,4-dioxane exposed group and control. PC1 accounted for 
29.1% of the variance, PC2 accounted for 21.3% of the variance, and PC3 accounted for 13% of 
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the variance. The results of the PCA indicated that further multivariate statistical analysis was 
necessary to discern the relationship between these two groups. 
To further identify features that contribute to segregation of metabolomes between control 
and exposed groups, partial least-squares discriminant analysis (PLS-DA) with Benjamini, Krieger 
and Yekutieli correction was applied to understand the different metabolomic patterns and identify 
potential biomarkers showing prominent concentration changes. As shown in figure 4, the 
clustering of the control and 1,4-dioxane exposed groups could be clearly discriminated. The R2X, 
R2Y, and Q2 (cum) of PLS-DA were 0.75, 0.98, and 0.41, respectively, indicating models are of 
good quality and could provide accurate predictions. The PLS-DA loading plots displayed 
variables that correlated with the score plots and demonstrated several crucial variables that were 
far from the center of the coordinate, indicating that these variables played an important role in 
clustering. (Figure 4). The variable importance in projection (VIP) plot displayed 15 variables with 
a value >1.0 (Figures 4). Of these, 11 were discovered as influential variables which after Students 
t-test had p-values <0.05 and q-values <0.016. Table 2 details each features listed with their 
corresponding retention time, m/z, mean concentration per group, and differences group. 
Interestingly, most of the metabolites were downregulated in the exposed group. 
Supervised orthogonal projection to latent structure analysis (OPLS-DA) with Benjamini, 
Krieger and Yekutieli correction was subsequently performed to identify features that contribute 
to segregation of features. OPLS-DA models provided strong differentiation in features between 
1,4-dioxane exposed group and control group (Figure 5). In order to find the metabolites affected 
by the 1,4-dioxane exposure, features significantly elevated or depleted in stool were selected 
using a cut-off value of P(corr) >.70 or P(corr)<.70 from the S-plot constructed from the respective 
OPLS-DA models (figure 5).  S-plots showed a plethora of features  contributing to the separation 
of the two groups (figure 5). These features were cross-checked with raw data and p-values 
generated using a Student's t-Test. Exploration from the 15 selected most distinct features (highest 
P(corr) values) suggested 9 influential features with p-value < 0.04 and q-values < 0.02. Potential 
biomarkers from OPLS-DA are summarized in Table 3 with their corresponding retention time, 
m/z, mean concentration per group, and differences between groups. Of note, seven of the 
influential features were also identified by the PLS-DA, and two additional features 
(197.09758/29.882, 565.25723/32.275) were identified using OPLS-DA that were not significant 




At present only the metabolic feature identifiers (m/z, RT) that were significantly 
correlated with 1,4-dioxane exposure were noted, formal identification of these features to 
metabolite names will be carried out in future studies. This will involve fragmentation analysis by 
mass spectrometry, correlation of fragments to metabolite databases and final confirmation of 
identity to a standard compound. In the Johnson Lab, a metabolite library exists of about 200 
compounds. We used this library to further mine the OPLS-DA data, for the remaining features 
which had a threshold of VIP ≥ 1.0. and Sig-plot cut-off value of P(corr) >.70 or P(corr)<.70. As 
it can be seen on Figure 6, alpha-tocopherol (vitamin E), threonine and citrulline, were found to 
be significantly lower in abundance in the 1,4-dioxane exposed group compared to the control 
(p=0.02, 0.02, 0.05 and q= 0.20, 0.20, 0.32, respectively). In total, sixteen potential biomarkers 
were identified, and are summarized in table 4 with their corresponding p-value, q-value, mean, 
difference by group.  
Discussion	
	
The cyclic ether 1,4-dioxane is generated as a byproduct in petrochemical industrial 
processes and has been widely utilized as a stabilizer for chlorinated solvents19–21. Due to its 
toxicity and high mobility, groundwater contamination by 1,4-dioxane is a serious and significant 
concern over a large geographical region22,23. For this reason, 1,4-dioxane concentrations in public 
and ground waters are strictly regulated in Japan at below 0.05 mg and those in the treated 
wastewater at below 0.5 mg24.  No federal or state MCLs have been established in United State, 
because the underlying mechanism of 1,4-dioxane toxicity is not fully understood4. It urges the 
needs of more comprehensive studies at the molecular level to decode the complex toxicogenesis 
and pathogenesis of 1,4-dioxane. Amino acid-conjugated primary bile acids are formed in the liver 
and excreted into the small intestine14,25. They are further deconjugated and hydrolyzed to 
secondary bile acids in the colon and excreted into the stool14,25. They can also undergo 
enterohepatic recirculation to the liver. Bile acid metabolism can be readily measured in the stool, 
dysregulation of which could indicate important malfunctions and diseases in human body, 
including those related to the liver. 25–28.  By exploring the effects of 1,4-dioxane metabolism from 
a systems biology approach in the stool, we hope to understand 1) bile acid and potential liver 
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dysfunction, and 2) the more widespread and as yet unknown effects of 1,4-dioxane on 
metabolism, as evidenced in changes to stool metabolites.  
Bile acid metabolism and intestinal microbiota are closely linked together29–31. Intestinal 
microbiota are involved in the biotransformation of bile acids through deconjugation and 
dehydroxylation of bile acids14,26. It is suggested that intestinal microbes generate short chain fatty 
acids from dietary carbohydrates that otherwise cannot be used as energy32. Therefore, intestinal 
microbiota composition directly affects energy metabolism, leading to remarkable alterations of 
lipid, glucose and energy metabolism in the liver, muscle, and adipose32,33. Recent evidence 
suggests that increased biliary secretion of bile acids may reshape the intestinal microbiota in 
diseases34. Feeding rats with a CA-containing diet resulted in increased intestinal Firmicutes-to-
Bacteroidetes ratio. DCA, escaped from reabsorption in the small intestine, enters the colon and 
exhibits the most potent antimicrobial activity and selective inhibition of intestinal bacteria growth, 
leading to altered composition of intestinal microbiota35. Another study showed that dietary 
saturated fats induced TCA, which promotes expansion of low-abundance sulfur-reducing 
pathobiont, Bilophila Wasdworthia, increases proinflammatory cytokines and incidence of colitis 
in il-10−/− mice36. In our study, no significant bile acid alteration was found. However, a trend of 
upregulation in LCA and HDCA were observed. (p= 0.12, 0.12, respectively). A trend of down 
regulation of TCA/CA  ratio in exposed group was also observed (p= 0.31). Previous study 
suggested secondary bile acids such as LCA could activate subtype-3 muscarinic receptors, an 
activation important for cancer progression37. Another study also suggested LCA not only 
produced a marked increase in the expression of epidermal growth factor receptor but also greatly 
activated epidermal growth factor receptor, which were responsible for tumorigenesis38. Previous 
study also suggested HDCA could activate liver X receptors that causing accumulation of lipid in 
the liver39. These observations indicated that changes in stool metabolic signatures may reflect 
extensive reprogramming of the bile acid metabolic pathway when exposed to 1,4-dioxane. 
 
 In addition to bile acids, several metabolites were also found dysregulated in this study. 
According to the untargeted metabolomic profiling, principal component analysis suggested there 
was modest discrimination between exposed group and control at week one. PC1 accounted for 
29.1% of the variance, while PC2 accounted for 21.3% of the variance, suggesting exposure to 
1,4-dioxane may account for 29.1% of difference in the stool metabolome.  Further PLS-DA and 
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OPLS-DA suggested distinct discrimination between the exposed group and control group. In 
both, PLS-DA and OPLS-DA analysis, the horizontal component of score scatter plots were clearly 
separated between the exposed and control, while the vertical components of score plots were less 
centered in control group compared to the exposed group, suggesting individual variation existed 
within the groups. In relation to human populations, inter-individual variation, such as life style 
and genetic polymorphism, could play influential roles in liver detoxification and metabolism. 
Previous study suggested heterozygous C282Y mutation of the gene for human hemochromatosis 
protein (HFE) was associated with genotype appear to be at an increased risk for liver cirrhosis, 
while heterozygous C282Y and homozygous H63D mutations in HFE were linked to liver cirrhosis 
in men, not in women 40,41. This may further explain for less discriminated result of the PCA scree 
plot and heatmap because individual variances may occur in our sample.  
Looking into the VIP plot derived from PLS-DA, eleven significant features were 
discovered as potential metabolite. Further, we identified metabolites with our in-house library 
and METLIN, according to features of a threshold of VIP ≥ 1.0. and Sig-plot cut-off value of 
P(corr) >.70 or P(corr)<.70. Vitamin E, threonine, citrulline, and pantothenic acid (vitamin B5) 
were found to be significantly dysregulated in 1,4-dioxane exposed group compared to the control 
group.  
Vitamin E and trends of vitamin B5 dysregulations were observed in our study when 
exposed to 1,4-dioxane. Vitamin E acts as a lipid-soluble antioxidant in cell membranes, where 
many of its functions can be provided by synthetic antioxidants, and is important in maintaining 
the fluidity of cell membranes42–45. In vivo and in vitro studies have shown that vitamin E functions 
as a chain-breaking antioxidant acting to protect unsaturated lipids from peroxidation by 
scavenging peroxyl radicals46,47. Dysregulation of vitamin E metabolism could lead to increasing 
oxidative stress and cancer. Vitamin B5 (pantothenic acid) plays an important role in synthesizing 
coenzyme-A (CoA) that  metabolizes proteins, carbohydrates, and fats48. Pantothenic acid has a 
central role in acyl group metabolism when acting as the pantetheine functional moiety of 
coenzyme A (CoA) or acyl carrier protein (ACP)48. It takes part in reactions of the citric acid cycle, 
fatty acid oxidation, acetylation, and cholesterol synthesis48. Vitamin B5 is involved in synthesis 
of fatty acid and is important in lowering cholesterol and levels of blood triglycerides, 
dysregulation of which may lead to  dysregulation of lipid metabolism and coenzyme function. 
Other than vitamins, amino acids such as threonine and citrulline were also dysregulated. 
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Threonine is an essential amino acid in mammals, which involves in liver lipotropic functions 
when combined with aspartic acid and methionine49,50. Citrulline is synthesized in the urea cycle 
by the addition of carbon dioxide and ammonia to ornithine51. Citrulline could reduce the damage 
to mitochondria in hepatocytes and could reduce the cell membrane lipid peroxidation and 
enhanced the activity of superoxide dismutase  in septic rats52. In our study, vitamin E, threonine 
and citrulline were significantly down regulated, which may lead to increased oxidative stress and 
suggested an increased risk of liver inflammation and toxification.   
The major limitation of this study is the relatively small sample size that may understate 
potential differences. A larger study that includes a larger sample size with longer exposure time 
frame is implied to understand the metabolomic network. In addition, the difficulty in identifying 
all metabolites in the stool limits the ability to fully resolve the identity of the taxa that may be 
important for the development of liver diseases and cancers. Inter-species alteration should also 
be taken into account. In humans, the highly hydrophobic bile acid pool consists of about 40% 
each of CA and CDCA, and 20% DCA, while in mice, the highly hydrophilic bile acid pool 
consists of about 50% CA and 50% α- and β-MCAs25. Moreover, a detailed analysis of pathways 
and signaling networks of differentially expressed metabolites is suggested to reveal the 
interrelatedness among these signaling pathways. The other concern is that this study may not 
provide a direct association between stool metabolome and liver diseases. This may be due to the 
dose of 1,4-dioxane exposure is still relatively small, which may require longer duration for a 
disease to establish. To fully evaluating the association between stool metabolome and liver 
diseases, biochemistry tests such as blood bilirubin, AST, ALT, albumin and tumor biomarker 




Stool metabolomic is an easy and non-invasive approach to study human body and 
diseases. Stool metabolome is affected by gut microbiota that could impact whole body metabolic 
homeostasis via the modulation of bile acid signaling and coordination between energy 
metabolism. Previous studies have suggested bacterial dysbiosis were associated with many 
diseases, including inflammatory bowel diseases, obesity, type 2 diabetes mellitus (T2DM), 
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nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and cancer37,53–55. As a result, measuring 
the biomarkers in the stool could reflect the well-being of a person and could be utilized for 
screening diseases and exposures, including environmental toxicants.  
Our previous study suggested 1,4-dioxane could alter liver function that was associated 
with liver carcinogenesis. We aimed to study whether the exposure would also affect stool 
metabolome, from which we could discover potential biomarkers for the exposure or disease. This 
study justified exposure to 1,4-dioxane would alter the metabolomic network in the stool. In 
particular, exposure to 1,4-dioxane down regulated vitamin E, vitamin B5, threonine and citrulline. 
These metabolites were essential for regulating cancer metabolism and inflammation such as 
oxidative stress, lipid metabolism, co-enzyme synthesis. The result greatly implicated the 
environmental toxicant 1,4-dioxane in drinking water could disrupt normal balance of intestinal 
microbiota and provide evidence toward its carcinogenesis. We hope this study would enlighten 
government legislator to take action in providing safe and clean water for citizens of United States. 
We also hope this study could inspire future studies to continue working on deciphering the 




 Stool metabolomics provides a complementary functional readout of microbial 
metabolism as well as its interaction with the host and environmental factors. The intestinal 
metabolites communicate with the enterohepatic systems to regulate host homeostasis, including 
bile acid circulation and liver functions. In this study, we found 1,4-dioxane dysregulated stool 
metabolome and down regulated vitamin E, threonine and citrulline metabolism.  A trend of bile 
acid dysregulation was also observed. Future pathway analysis studies are needed to confirm the 
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Target bile acid metabolomics with multiple t-test with Benjamini, Krieger and Yekutieli 
correction revealed a trend of upregulation in LCA (p= .12) and HDCA (p= .12), and a trend of 






























































 Columns on heatmap represent samples. Rows are representative metabolites that are evaluated 
for dysregulation. Heatmap suggested modest discrimination between control group and 1,4-













Principle component score plots showed top PCs. Figure 1A. depicts 3D plot of PCs. PC1 
accounted for 29.1% of the variance, PC2 accounted for 21.3% of the variance, and PC3 accounted 




















































































































































Figure 4A. PLS-DA showed discrimination between 1,4-dioxane exposed group and control group 
in two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 20%. (R2X: 
0.75, R2Y: 0.98, Q2: 0.41). Figure 4B. The PLS-DA loading plots displayed variables that 
correlated with the score plots and demonstrated several crucial variables. Figure 4C. Variable 
importance in projection (VIP) plot displayed the top 15 most important metabolite features 
identified by PLS-DA. Figure 4D. Colored boxes on right indicate relative abundance of 
corresponding metabolite between control group and 1,4-dioxane exposed group. Figure 4E.  














































































































































































Figure 5A. OPLS-DA showed discrimination between 1,4-dioxane exposed group and control 
group in two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 20%. 
(R2X = 0.192, R2Y = 0.921, Q2 = 0.5). Figure 5B. The OPLS-DA Sig plots displayed variables 
that correlated with the score plots and demonstrated several crucial variables. Figure 5C. 
Metabolites significantly elevated or depleted in stool were selected using a cut-off value of P(corr) 
>.70 or P(corr)<.70 from the Sig plot. Figure 5D. Fifteen most marked features were discovered 
















































































































Figure 6A. Metabolites Figure 6B. Vitamin E, Threonine and Citrulline were down regulated in 









































difference t ratio q value 
CA 0.712 2.638 2.780 -0.142 0.3670 0.387 >0.999 
CDCA 0.330 2.109 2.395 -0.286 0.2698 1.059 >0.999 
DCA 0.562 3.118 3.026 0.0919 0.1498 0.614 >0.999 
LCA 0.123 0.774 1.128 -0.355 0.1984 1.789 >0.999 
UDCA 0.370 2.466 2.750 -0.284 0.2936 0.968 >0.999 
TCA 0.506 2.613 2.487 0.126 0.1784 0.708 >0.999 
TCDCA 0.980 1.323 1.333 -0.010 0.3838 0.026 >0.999 
TDCA 0.865 1.496 1.558 -0.063 0.3520 0.178 >0.999 
GDCA 0.458 0.844 0.6958 0.148 0.1870 0.793 >0.999 
HDCA 0.123 2.618 3.078 -0.460 0.2562 1.795 >0.999 
THDCA 0.496 2.606 2.478 0.128 0.1767 0.725 >0.999 
TCA/CA 0.313 -0.025 -0.293 0.268 0.2435 1.101 >0.999 
TDCA/DCA 0.721 -1.622 -1.467 -0.155 0.4123 0.375 >0.999 
TCDCA/CDCA 0.545 -0.786 -1.061 0.276 0.4298 0.642 >0.999 

































difference t ratio q value 
389.26965/101.437 0.013 7.583 7.316 0.266 0.077 3.478 0.005 
506.25909/38.878 0.001 7.217 6.631 0.586 0.103 5.683 0.001 
480.24225/38.564 0.001 7.210 6.607 0.604 0.093 6.432 0.001 
391.34488/141.02 0.225 6.332 4.651 1.680 1.243 1.352 0.062 
466.31176/22.5705 0.005 7.366 7.185 0.180 0.0416 4.333 0.003 
373.20663/26.968 0.106 7.259 6.992 0.267 0.140 1.901 0.032 
194.04892/88.001 0.274 7.339 6.728 0.612 0.508 1.203 0.071 
275.02712/45.422 0.941 5.811 5.901 -0.0899 1.178 0.076 0.226 
548.30524/33.535 0.002 6.892 6.349 0.543 0.107 5.095 0.002 
552.33742/33.651 0.004 6.878 6.305 0.573 0.129 4.454 0.003 
493.33234/22.1415 0.001 7.142 6.948 0.194 0.034 5.683 0.001 
493.33649/22.142 0.001 7.128 6.934 0.194 0.034 5.663 0.001 
465.30969/22.4235 0.049 7.377 7.238 0.139 0.057 2.457 0.016 
189.97297/30.9465 0.012 6.942 6.625 0.317 0.090 3.534 0.005 











difference t ratio q value 
275.02712/45.422 0.941 5.811 5.901 -0.090 1.178 0.076 0.301 
217.00233/151.112 0.730 7.216 7.140 0.076 0.210 0.362 0.250 
241.21783/39.509 0.095 6.195 6.624 -0.428 0.216 1.980 0.045 
96.96024/482.0485 0.549 4.072 4.134 -0.062 0.098 0.634 0.203 
301.16407/309.936 0.103 6.285 6.609 -0.324 0.169 1.919 0.045 
565.25723/32.275 0.036 5.340 6.202 -0.862 0.321 2.686 0.019 
197.09758/29.882 0.002 4.047 4.285 -0.238 0.045 5.289 0.002 
389.26965/101.437 0.013 7.583 7.316 0.266 0.077 3.478 0.008 
480.24225/38.564 0.001 7.210 6.607 0.604 0.094 6.432 0.002 
506.25909/38.878 0.001 7.217 6.631 0.586 0.103 5.683 0.002 
466.31176/22.5705 0.005 7.366 7.185 0.180 0.042 4.333 0.003 
493.33234/22.1415 0.001 7.142 6.948 0.194 0.034 5.683 0.002 
548.30524/33.535 0.002 6.892 6.349 0.543 0.107 5.095 0.002 
552.33742/33.651 0.004 6.878 6.305 0.573 0.129 4.454 0.003 




















high  Difference 
SE of 
difference t ratio q value 
Citrulline 0.053 3.285 2.879 0.406 0.169 2.405 0.321 
Aspartate 0.158 3.889 3.586 0.303 0.188 1.614 0.478 
Glutamate 0.617 2.880 2.801 0.0792 0.150 0.528 0.863 
Alanine 0.239 3.335 3.096 0.240 0.184 1.307 0.621 
Threonine 0.023 3.142 2.917 0.225 0.074 3.038 0.208 
Taurine 0.424 5.040 4.624 0.416 0.486 0.857 0.772 
Lysine 0.123 2.680 2.539 0.141 0.079 1.794 0.448 
Fructose 6-
phosphate 0.502 4.448 4.227 0.221 0.310 0.714 0.792 
DHAPorG3P 0.361 3.015 2.850 0.165 0.167 0.988 0.730 
Glucosamine 6-
phosphate 0.901 2.678 2.662 0.017 0.128 0.130 >0.999 
UDP-N-
acetylglucosamine 0.884 2.737 2.759 -0.022 0.147 0.153 >0.999 
Cytidine 0.522 4.298 4.493 -0.196 0.288 0.680 0.792 
2'-Deoxyuridine 0.339 4.193 3.980 0.212 0.204 1.039 0.730 
UDP-D-Glucose 0.860 2.598 2.609 -0.011 0.058 0.184 >0.999 
Pantothenate 0.090 5.424 4.991 0.433 0.215 2.015 0.412 
Vitamin E 0.020 5.190 5.014 0.176 0.056 3.113 0.208 
 
 
 
 
 
 
 
 
